Latest / The Founder's Journey with Fexingo: First-Time Entrepreneurs, Failures, and Lessons Learned / How a Rejected Patent Built a 45M MedTech Company
Transcript
- Lucas: So you know how sometimes the worst rejection turns out to be the best thing that ever happened to you? Luna: I feel like that's the theme of this whole show. Lucas: Right. But today's story takes that to a literal extreme. A founder named Priya Sharma filed a patent for a wearable sensor that monitors glucose levels non-invasively. The patent office rejected it. Not because it was obvious, but because they said the technology was too speculative. Luna: Ouch. That's a tough one. I'd be crushed. Lucas: She was. But instead of giving up, she took that rejection and turned it into a 45 million dollar company. And the twist is, the company doesn't even sell the sensor anymore. Luna: Wait, what? Then what do they sell? Lucas: They sell the software. Think of it as the analytical brain behind continuous glucose monitors. They pivoted from making the hardware to making the platform that interprets the data. And that pivot was directly inspired by the patent rejection. Luna: So the rejection forced them to rethink their whole model? Lucas: Exactly. The patent office basically told her, 'Your sensor idea isn't ready for prime time.' But the data analytics behind it? That was solid. And that's where she doubled down. Luna: I love that. Sometimes you need someone else to show you where your real value is. Lucas: And it wasn't just the patent office. She went to VCs with the original hardware pitch and got turned down by, I think, fourteen firms. The feedback was always the same: hardware is capital intensive, regulatory hurdles are high, and the market wasn't ready. Luna: Fourteen rejections. That's brutal. But I'm guessing the fifteenth pitch was different. Lucas: Yeah, the fifteenth was the one that worked. But she didn't go in with the same pitch. She went in with a software story. She said, 'Look, we're not selling the hardware. We're selling the algorithm that makes any continuous glucose monitor smarter.' Luna: That's a completely different company. Lucas: It was. And that's what got the funding. They raised a seed round of 2 million dollars, and then they got their first FDA clearance for their software as a medical device. That was the turning point. Luna: So they went from patent rejection to FDA clearance. How long did that whole journey take? Lucas: From the initial rejection to the FDA clearance was about four years. And they had to go through several iterations of the software, work with clinical partners, and build a data set that proved the algorithm was accurate. Luna: That's a long grind. What kept her going? Lucas: She said it was the belief that the data could genuinely change how people manage diabetes. Every time she wanted to quit, she'd talk to a patient who told her their glucose levels had been erratic for years, and she thought, 'We can fix that.' Luna: That's powerful. It's not just about building a business; it's about having a mission. Lucas: And that mission paid off. Today, their software is used by over 200,000 patients, and they've partnered with two of the biggest glucose monitor manufacturers. Their revenue hit 45 million dollars last year. Luna: That's incredible. And it all started with a 'no' from the patent office. Lucas: It's a classic example of turning a constraint into a catalyst. The rejection forced them to be honest about what they could realistically build and sell. Luna: I think that's a lesson for any founder listening. Sometimes the rejection is just a redirection. Lucas: Exactly. And I love that they didn't just pivot to something random. They pivoted to the thing they were actually best at. That's the smart part. Luna: So what's next for them? Are they planning to go back to hardware at some point? Lucas: They've said they're open to it, but only if the technology matures and the regulatory path becomes clearer. For now, they're focused on expanding their software platform to other chronic conditions like heart disease. Luna: That's a smart move. They're building a platform, not just a product. Lucas: And that's what investors love. It's a scalable model with recurring revenue. Their ARR is growing at about 40 percent year-over-year. Luna: That's impressive. I'd love to hear more about the team. How did she build the right people around her? Lucas: She said the key was hiring for grit over Ivy League credentials. Her head of engineering was a self-taught coder who had never worked in health tech before. But he was obsessed with solving complex problems. Luna: That's a refreshing approach. Sometimes the best people come from unexpected places. Lucas: Definitely. And she was also very intentional about building a diverse team. She said that when you're building for patients, you need people who understand different perspectives. Luna: That makes a lot of sense. Health care isn't one-size-fits-all. Lucas: Right. And I think that mindset is part of why their software has been so well received. It's not just an algorithm; it's an algorithm that has been trained on a diverse data set. Luna: I'm curious about the financial side. Did they have to raise a lot of money to get to this point? Lucas: They've raised about 20 million dollars in total. But they've been careful about not over-diluting. They started with a small seed round, then a Series A, and then a Series B last year. They've kept their burn rate low by focusing on partnerships rather than building everything in-house. Luna: That's a disciplined approach. A lot of startups blow through cash trying to do everything themselves. Lucas: Exactly. And it's worked. They're now profitable, which is rare for a MedTech company at this stage. Luna: That's a huge milestone. So, any advice for founders who are facing their own patent rejections? Lucas: She'd say, 'Don't take it as a verdict on your idea. Take it as feedback on your approach.' And that's a mindset shift I think we can all learn from. Luna: Yeah, that's something we should all remember. On that note, we like to keep these conversations free from ads and accessible to everyone. If you've found value in our episodes, you can support us at buy me a coffee dot com slash fexingo. Lucas: It's a small gesture that goes a long way in keeping this show independent. We're not asking for a lot, just enough to cover the hosting costs and maybe a few coffees for us. Luna: Exactly. And now, back to Priya's story — what do you think is the biggest takeaway for a first-time founder listening to this? Lucas: I think it's that rejection is not the end. It's a data point. And if you're willing to listen, it can tell you exactly where you need to pivot. Luna: I couldn't agree more. Thanks for joining us on this journey today.